Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07001319 · ClinicalTrials.gov registry record · Phase 1

Study of GS-3242 in Participants With HIV-1; Substudy-05

A Phase 1 study of HIV-1-infection, sponsored by Gilead Sciences.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
20
Study locations

NCT07001319 is a Phase 1 study of HIV-1-infection that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 30 participants, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07001319, a Phase 1 study of HIV-1-infection, is actively recruiting participants, sponsored by Gilead Sciences.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
20
Study locations

Study Summary

This study is part of a master study. The goal of master protocol (GS-US-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). Substudy GS-US-544-5905-05 is to learn more about the study drug GS-3242 in PWH.

Conditions Studied

HIV-1-infection

Interventions

  • DRUG GS-3242
  • DRUG BVY
  • DRUG Standard of Care

Study Locations (20)

Florida

  • Midland Florida Clinical Research Center, LLC - DeLand
  • AIDS Healthcare Foundation - Northpoint - Fort Lauderdale
  • Midway Immunology & Research Center, LLC - Ft. Pierce
  • BLISS Health - Orlando
  • Orlando Immunology Center, PA - Orlando
  • Triple O Research Institute, P.A. - West Palm Beach

California

  • Franco Felizarta, MD - Bakersfield
  • Ruane Clinical Research Group, Inc - Los Angeles
  • Mills Clinical Research - Los Angeles
  • Quest Clinical Research - San Francisco

Texas

  • Central Texas Clinical Research - Austin
  • Prism Health North Texas - Dallas
  • North Texas Infectious Diseases Consultant's, P.A. - Dallas
  • AXCES Research Group, LLC - El Paso

District of Columbia

  • Washington Health Institute - Washington D.C.

Georgia

  • Chatham County Health Department - Savannah

Indiana

  • Indiana University School of Medicine - Indianapolis

Michigan

  • Be Well Medical Center - Berkley

Missouri

  • KC CARE Health Center - Kansas City

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-05-29
Est. Completion 2027-02
Phase Phase 1

Sponsor

Gilead Sciences

504 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07001319

The ClinicalTrials.gov registry entry for NCT07001319 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (91% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 3 interventions - of which GS-3242 is the first listed.

NCT07001319 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Texas.

Frequently Asked Questions

What is clinical trial NCT07001319 about?

NCT07001319 is a clinical study titled "Study of GS-3242 in Participants With HIV-1; Substudy-05". This study is part of a master study. The goal of master protocol (GS-US-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). Substudy GS-US-544-5905...

What is the current status of trial NCT07001319?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-05-29. Estimated completion is 2027-02.

What conditions does trial NCT07001319 study?

This clinical trial studies the following conditions: HIV-1-infection.

What interventions are being tested in trial NCT07001319?

The interventions under investigation include: GS-3242 (DRUG), BVY (DRUG), Standard of Care (DRUG).

Who is sponsoring clinical trial NCT07001319?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07001319 being conducted?

This trial has 20 study locations across California, District of Columbia, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV-1-infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV-1-infection

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.